UBS Sets $29 Price Target on Mineralys Therapeutics
UBS initiated coverage of Mineralys Therapeutics at Neutral and set a $29.00-per-share price target.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.